Drug intelligence / Profile preview

shenjingfuyuanfang

Development stage: Unknown
Lead developer: Shanghai Municipal Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Shenjingfuyuanfang is a Traditional Chinese Medicine (TCM) herbal formula developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is formulated as granules for oral administration and is primarily investigated for the secondary prevention of mild ischemic stroke. The formula is specifically designed to address TCM patterns of Qi and Yin deficiency accompanied by phlegm and blood stasis, which are common pathological states in the non-acute phase of stroke. The therapeutic goal of the treatment is to reduce neurological impairment and decrease the risk of stroke recurrence through the synergistic effects of its constituent botanical extracts.

Other names: Shenjing Fuyuan FangShenjing Fuyuan formula

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on shenjingfuyuanfang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shenjingfuyuanfang.

Explore the full profile